TY - JOUR
T1 - Comparison of histological changes and changes in nm23 and c-MET expression between primary and metastatic sites in osteosarcoma
T2 - A clinicopathologic and immunohistochemical study
AU - Oda, Yoshinao
AU - Naka, Takahiko
AU - Takeshita, Morishige
AU - Iwamoto, Yukihide
AU - Tsuneyoshi, Masazumi
N1 - Funding Information:
From the Department of Anatomic Pathology and the Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kyushu University, and the Department of Pathology, Kyushu National Medical Center, Fukuoka, Japan. Accepted for publication February 24, 2000. Supported in part by a Grant-in-Aid for Cancer Research from the Fukuoka Cancer Society, Fukuoka, and Grant-in-Aid for Scientific Research (10307034 and 09557124) from the Ministry of Education, Science, Sports and Culture, Tokyo,Japan. Address correspondence and reprint requests to Masazumi Tsuneyoshi, MD, Department of Anatomic Pathology (Second Department of Pathology), Pathological Sciences, Graduate School of Medical Sciences, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582,Japan. Copyright © 2000 by W.B. Saunders Company 0046-8177/00/3106-0013510.00/0 doi: 10.1053/hupa.2000.8230 reaction for c-MET in the primary site showed immunoreactivity for c-MET in the metastatic site. Although there was no statistical significance, c-MET expression seemed to be more frequent in the metastatic site, compared with the primary site. Among the overall tumors, c-MET-positive tumors showed significantly higher MIB-1 LI, compared with c-MET-negatlve tumors (negative, 20.99; positive, 27.65; P = .0292). No significant change was observed regarding p53 and MDM2 between the primary and metastatic site. Our results suggest that rather than being a metastasis-suppressor gene, rim23 is in fact correlated with metastatic progression in osteosarcoma. Positive correlation between c-MET expression and proliferative activity also suggests that c-MET expression may play an important role in tumor progression in osteosarcomas. HUM PATHOL 31:709-716. Copyright © 2000 by W.B. Satmders Company Key words: osteosarcoma, metastasis, nm23, C-MET, p23, MDM2.
PY - 2000
Y1 - 2000
N2 - Changes in morphological features between the primary and metastatic sites in osteosarcoma and the role of nm23 protein and c-MET oncogene product have remained controversial. In addition to histological studies, we evaluated the expression of nm23, c-MET, p53, and MDM2 immunohistochemically using 25 osteosarcomas in which both primary and concordant metastatic specimens were available. Moreover, we assessed proliferative activity using the monoclonal antibody MIB-1. Among these 25 cases, 4 tumors that were osteoblastic type (16%) in the primary site had changed morphologically to MFH-like type in the metastatic site, whereas 2 MFH-like type and 1 small cell-type tumors had changed to osteoblastic type. MIB-1 LI was significantly higher in the metastatic site than in the primary site (primary, 20.02; metastatic, 26.72; P= .0209). Seventeen cases (68%) showed increased nm23 expression in the metastatic site, whereas 2 cases showed reduced expression, nm23 expression was significantly increased in the metastatic site, compared with the primary site (P = .0009). Seven cases (28%) showing negative reaction for c-MET in the primary site showed immunoreactivity for c-MET in the metastatic site. Although there was no statistical significance, c-MET expression seemed to be more frequent in the metastatic site, compared with the primary site. Among the overall tumors, c-MET-positive tumors showed significantly higher MIB-1 LI, compared with c-MET-negative tumors (negative, 20.99; positive, 27.65; P =.0292). No significant change was observed regarding p53 and MDM2 between the primary and metastatic site. Our results suggest that rather than being a metastasis-suppressor gene, nm23 is in fact correlated with metastatic progression in osteosarcoma. Positive correlation between c-MET expression and proliferative activity also suggests that c-MET expression may play an important role in tumor progression in osteosarcomas. (C) 2000 by W.B. Saunders Company.
AB - Changes in morphological features between the primary and metastatic sites in osteosarcoma and the role of nm23 protein and c-MET oncogene product have remained controversial. In addition to histological studies, we evaluated the expression of nm23, c-MET, p53, and MDM2 immunohistochemically using 25 osteosarcomas in which both primary and concordant metastatic specimens were available. Moreover, we assessed proliferative activity using the monoclonal antibody MIB-1. Among these 25 cases, 4 tumors that were osteoblastic type (16%) in the primary site had changed morphologically to MFH-like type in the metastatic site, whereas 2 MFH-like type and 1 small cell-type tumors had changed to osteoblastic type. MIB-1 LI was significantly higher in the metastatic site than in the primary site (primary, 20.02; metastatic, 26.72; P= .0209). Seventeen cases (68%) showed increased nm23 expression in the metastatic site, whereas 2 cases showed reduced expression, nm23 expression was significantly increased in the metastatic site, compared with the primary site (P = .0009). Seven cases (28%) showing negative reaction for c-MET in the primary site showed immunoreactivity for c-MET in the metastatic site. Although there was no statistical significance, c-MET expression seemed to be more frequent in the metastatic site, compared with the primary site. Among the overall tumors, c-MET-positive tumors showed significantly higher MIB-1 LI, compared with c-MET-negative tumors (negative, 20.99; positive, 27.65; P =.0292). No significant change was observed regarding p53 and MDM2 between the primary and metastatic site. Our results suggest that rather than being a metastasis-suppressor gene, nm23 is in fact correlated with metastatic progression in osteosarcoma. Positive correlation between c-MET expression and proliferative activity also suggests that c-MET expression may play an important role in tumor progression in osteosarcomas. (C) 2000 by W.B. Saunders Company.
UR - http://www.scopus.com/inward/record.url?scp=0033938552&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033938552&partnerID=8YFLogxK
U2 - 10.1053/hupa.2000.8230
DO - 10.1053/hupa.2000.8230
M3 - Article
C2 - 10872665
AN - SCOPUS:0033938552
SN - 0046-8177
VL - 31
SP - 709
EP - 716
JO - Human Pathology
JF - Human Pathology
IS - 6
ER -